Comparison of the effectiveness of oral morphine versus oral tramadol on early pain control in opioid-naive patients with moderate cancer pain.

Authors

Ramila Shilpakar

Ramila Shilpakar

NAMS, Bir Hospital, Kathmandu, Nepal

Ramila Shilpakar , Bishnu D. Paudel , Aarati Shah , Soniya Dulal

Organizations

NAMS, Bir Hospital, Kathmandu, Nepal, National Academy of Medical Sciences, Kathmandu, Nepal, National Academy of Medical Sciences (NAMS), Bir hospital, Kathmandu, Nepal

Research Funding

Other

Background: Adequate pain control, an essential part of cancer care remains a challenge in resource limited countries like Nepal. Early use of morphine for Moderate Cancer Pain (MCP) and not sequential World Health Organization (WHO) analgesic ladder seems reasonable in the setting of limited access to health care. The purpose of this study was to compare efficacy of oral Morphine (MOR) with oral Tramadol (TRM) in control of pain as well as physical wellbeing in patients (pts) with MCP using Edmonton Symptom Assessment Scale (ESAS). Methods: An IRB approved randomized phase II trial was performed in opioid-naive pts with MCP as defined by pain score in Numerical rating score (NRS)of 4-6.Patients were randomized to receive MOR syrup 5 mg 4 hourly or TRM 50 mg four times a day. Titration of dose was done in both groups for 3 days as per standard recommendation for MOR or till maximum recommended daily dose for TRM. MOR was changed to prolonged release form at Day 4.The primary endpoint was number of early responders, defined as pts with at least 20% reduction in pain intensity on NRS on Day 3. Secondary outcome was number of patients with highly meaningful pain reduction, defined as decrease in pain intensity on NRS by ≥ 5 and improvement in physical well-being with ESAS at Day 7. Results: 68 pts consented and were randomized, 34 in each arm. The primary endpoint occurred in 94.1% pts in MOR and 55.9% in TRM (p <0.001). Number of patients with highly meaningful pain reduction was significantly higher in MOR than in TRM (76.5% vs. 32.35%; p<0.001). Improvement in general physical wellbeing as assessed by ESAS was better in morphine group. No difference in adverse effects was noted between the treatment arms. Conclusions: In this study Morphine was superior to Tramadol in the control of pain with statistically significant difference in the primary and secondary endpoints. So, early use of morphine skipping the WHO sequential analgesic ladder for moderate cancer pain seems a higher value option in resource scarce country with limited access to healthcare.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Symptoms and Survivorship

Track

Symptom Science and Palliative Care

Sub Track

Palliative Care and Symptom Management

Citation

J Clin Oncol 37, 2019 (suppl; abstr 11581)

DOI

10.1200/JCO.2019.37.15_suppl.11581

Abstract #

11581

Poster Bd #

273

Abstract Disclosures

Similar Abstracts

First Author: Min Jung Geum

Abstract

2020 ASCO Virtual Scientific Program

Using oral morphine-equivalent values to track the analgesic effect of treatments in clinical trials.

First Author: Stephen A Raymond

Abstract

2024 ASCO Breakthrough

Opioid access barriers for cancer pain relief in Vietnam: A qualitative study.

First Author: Trang Nguyen